Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Old giants weather difficult economy - and Boston thrives

This article was originally published in Clinica

Executive Summary

2002 was not an easy year for Baxter International, what with the problems in its renal products department and doubts over its long-term growth potential, but it managed to struggle through with double-digit sales growth. And excluding special charges related to acquisitions and divestments, it achieved a respectable 15% increase in net profit to $1.24bn. Of the company's three operating divisions - medication delivery, renal and bioscience - the first was the strongest. Sales rose by 14% to $3.32bn, driven by anaesthesia devices and drug delivery products. Renal sales rose by just 2% to $1.7bn, and the company has decided to divest the services part of the business and focus on products.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT060925

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel